224 related articles for article (PubMed ID: 31906898)
21. Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
Fenske AE; Glaesener S; Bokemeyer C; Thomale J; Dahm-Daphi J; Honecker F; Dartsch DC
Cancer Lett; 2012 Nov; 324(2):171-8. PubMed ID: 22613583
[TBL] [Abstract][Full Text] [Related]
22. Biological markers of cisplatin resistance in advanced testicular germ cell tumours.
García-Velasco A; Durán I; García E; Tarón M; Ballestín C; Castellanos D; Cortés-Funés H; Paz-Ares L
Clin Transl Oncol; 2012 Jun; 14(6):452-7. PubMed ID: 22634534
[TBL] [Abstract][Full Text] [Related]
23. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
24. HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer.
Liu Y; Bernauer AM; Yingling CM; Belinsky SA
Carcinogenesis; 2012 Jun; 33(6):1187-92. PubMed ID: 22467238
[TBL] [Abstract][Full Text] [Related]
25. DNA repair gets physical: mapping an XPA-binding site on ERCC1.
Croteau DL; Peng Y; Van Houten B
DNA Repair (Amst); 2008 May; 7(5):819-26. PubMed ID: 18343204
[TBL] [Abstract][Full Text] [Related]
26. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
27. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Feldman DR; Iyer G; Van Alstine L; Patil S; Al-Ahmadie H; Reuter VE; Bosl GJ; Chaganti RS; Solit DB
Clin Cancer Res; 2014 Jul; 20(14):3712-20. PubMed ID: 24812411
[TBL] [Abstract][Full Text] [Related]
28. 14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.
Lai KK; Chan KT; Choi MY; Wang HK; Fung EY; Lam HY; Tan W; Tung LN; Tong DK; Sun RW; Lee NP; Law S
Tumour Biol; 2016 Feb; 37(2):2127-36. PubMed ID: 26346170
[TBL] [Abstract][Full Text] [Related]
29. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum group A and G proteins, which is mediated by calcineurin inhibition.
Kuschal C; Thoms KM; Boeckmann L; Laspe P; Apel A; Schön MP; Emmert S
Exp Dermatol; 2011 Oct; 20(10):795-9. PubMed ID: 21707758
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis regulation and spontaneous apoptosis index of testicular germ cell tumors are associated with differentiation and resistance to systemic treatment.
Mandoky L; Szende B; Géczi L; Bodrogi I; Kásler M; Bak M
Anticancer Res; 2008; 28(3A):1641-9. PubMed ID: 18630521
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin resistance in germ cell tumours: models and mechanisms.
Jacobsen C; Honecker F
Andrology; 2015 Jan; 3(1):111-21. PubMed ID: 25546083
[TBL] [Abstract][Full Text] [Related]
33. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance.
Wermann H; Stoop H; Gillis AJ; Honecker F; van Gurp RJ; Ammerpohl O; Richter J; Oosterhuis JW; Bokemeyer C; Looijenga LH
J Pathol; 2010 Aug; 221(4):433-42. PubMed ID: 20593487
[TBL] [Abstract][Full Text] [Related]
34. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.
Tsodikov OV; Ivanov D; Orelli B; Staresincic L; Shoshani I; Oberman R; Schärer OD; Wagner G; Ellenberger T
EMBO J; 2007 Nov; 26(22):4768-76. PubMed ID: 17948053
[TBL] [Abstract][Full Text] [Related]
35. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
Veenstra CM; Vaughn DJ
Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
[TBL] [Abstract][Full Text] [Related]
36. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
37. ERCC1-XPF targeting to psoralen-DNA crosslinks depends on XPA and FANCD2.
Sabatella M; Pines A; Slyskova J; Vermeulen W; Lans H
Cell Mol Life Sci; 2020 May; 77(10):2005-2016. PubMed ID: 31392348
[TBL] [Abstract][Full Text] [Related]
38. Domains in the XPA protein important in its role as a processivity factor.
Bartels CL; Lambert MW
Biochem Biophys Res Commun; 2007 Apr; 356(1):219-25. PubMed ID: 17349973
[TBL] [Abstract][Full Text] [Related]
39. The PDGFRβ-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors.
Juliachs M; Muñoz C; Moutinho CA; Vidal A; Condom E; Esteller M; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
Clin Cancer Res; 2014 Feb; 20(3):658-67. PubMed ID: 24277456
[TBL] [Abstract][Full Text] [Related]
40. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines.
Weaver DA; Crawford EL; Warner KA; Elkhairi F; Khuder SA; Willey JC
Mol Cancer; 2005 May; 4(1):18. PubMed ID: 15882455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
